6432results about "Endocrine system disorder" patented technology

A nitrogen-containing fused ring compound as a GLP-1 receptor agonist, and a preparation method therefor and the use thereof. Specifically, provided are a compound as represented by formula (I), and the use thereof in the preparation of a drug for treating or preventing diseases mediated by GLP-1.

The present invention relates to a new crystal form of Resmetirom and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation of a THR-β selective agonist pharmaceutical formulation and a pharmaceutical formulation for treating MASH and HeFH.

The invention discloses a nitrogen-containing bridged ring compound serving as a GLP-1 receptor agonist as well as a preparation method and application of the nitrogen-containing bridged ring compound. Specifically, the invention discloses a compound as shown in a formula (I), and application of the compound in preparation of drugs for treating or preventing GLP-1 mediated diseases. # imgabs0 #

The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

The invention provides a compound as shown in a formula I, or pharmaceutically acceptable salt, stereoisomer or tautomer thereof. The compounds have been demonstrated to be good GLP-1 receptor agonists. In addition, the compound is simple in preparation method and has a certain application prospect. # imgabs0 #

A synergistic composition for improving the bioaccessibility of minerals comprises lutein, a casein phosphopeptide, or a 1, 3-dioleoyl-2-palmitic acid triglyceride, preferably in combination with one or more non-digestible oligosaccharides. These compositions are useful for the prevention and / or treatment of mineral deficiency and related conditions, preferably anemia, said minerals comprising iron and / or calcium.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The invention discloses a vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions and a preparation method and application thereof, the vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions comprises three layers, namely a core layer, a middle layer and an outer layer from inside to outside in sequence; the core layer is formed by coating vitamin K2 with a zein-lac hydrophobic core, the middle layer is a pea protein-pectin electrostatic compound, and the outer layer is sodium alginate and chitosan double-network gel. The micro-capsule system provided by the invention can be tightly combined in a gastric acid environment after being orally taken, the release of active ingredients in the stomach is reduced, and then the micro-capsule system stays at intestinal mucosa for a long time and slowly releases contents, so that the functions of the micro-capsule system are slowly presented outside, the half-life period is prolonged, and the action effect is improved. Vitamin K2 directly or indirectly participates in and regulates various physiological processes related to health, and plays an important role in the aspects of maintaining bone health, preventing cardiovascular diseases, protecting nerves, improving metabolism and the like.

The invention provides a fenerenone pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical preparation prepared by the method disclosed by the invention has better stability, and the release effect of the pharmaceutical preparation is consistent with that of a reference preparation.

The invention relates to application of fermentation lactobacillus mucus LFPerfectuus001 in preparation of a product for improving metabolic syndrome caused by high-fat and high-sugar diet, and belongs to the technical field of microorganisms. The invention provides application of fermented lactobacillus mucus LFPerfecus001 in preparation of a product for improving metabolic syndrome, the fermented lactobacillus mucus LFPerfecus001 is preserved in Guangdong Microbial Culture Collection Center on April 13, 2022, and the preservation number is GDMCC No: 62335. The invention further provides a preparation method of the fermented lactobacillus mucus LFPerfecus001. Animal experiments report that the fermented lactobacillus mucus LFPerfectus001 has the effects of reducing fat, increasing muscle, improving obesity, hyperglycemia, insulin resistance, dyslipidemia, hyperuricemia and fatty liver for the first time, and can well improve metabolic syndrome caused by high fat and high glucose.

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, a prodrug or pharmaceutically acceptable salt thereof, which have better BRD4 inhibition and degradation effects as a drug, and can be used for preparing drugs related to BRD4 inhibition and degradation. And preventing and / or treating related diseases. # imgabs0 #

A segment of short-sequence polypeptide which can be separated in vitro is obtained through screening, and the short-sequence polypeptide is applied to polypeptide drugs such as analogues or derivatives of GLP-1, so that the stability of the polypeptide drugs can be improved, the action time of the polypeptide drugs can be prolonged, and the biological activity of the polypeptide drugs can be improved.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

The invention discloses polynucleotide, a pharmaceutical composition and application of the polynucleotide. In the application, a plurality of polynucleotide sequences targeting the 3'untranslated region of the nuclear fiber layer protein A mutant mRNA are newly designed, the expression level of the nuclear fiber layer protein A mutant (such as premature protein) can be reduced in the Lamin AmRNA stage, and meanwhile, the normal transcription of Lamin C is not influenced, so that the toxic and side effects are lower; the compound has a wide prospect in the aspect of preventing or treating diseases (especially progeria) related to mutation of the nuclear fiber layer protein A.

The invention discloses a polypeptide derivative with a GCGR, GIPR and GLP-1R triple targeting agonistic effect as well as a preparation method and application of the polypeptide derivative, the polypeptide derivative is shown as a formula (I), (II) is a branched chain modification structure of a peptide chain, and the group definition is detailed in the specification. The polypeptide derivative compound and the pharmaceutically acceptable salt thereof provided by the invention can be used for treating metabolic related diseases such as diabetes mellitus, weight loss, MASH and the like, cardiovascular and cerebrovascular diseases and / or neurodegenerative diseases. Tyr-Aib-Gln-Gly-Thr-Ph-Thr-Ser-Asp-Tyr-Ser-Xaa12-Xaa13-Leu-As-Lys-Xaa17-Ala-Gln-Xaa24-Xaa25-Leu-Leu-Xaa28-Gly-Ala-Pro-Pro-Ser-NH2 (I) # imgabs0 #

The invention provides gastric residence systems with specifically tailored architectures and methods for making such systems. The components of the gastric residence systems can be manufactured by three-dimensional printing or by co-extrusion. The ability to construct precise architectures for the systems provides excellent control over drug release, in vivo stability, and residence time of the systems.

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby improving properties of the finished drug.

To provide an oil-based solid composition for external use having excellent stability. An oil-based solid composition for external use is prepared that comprises: (A) an oily component with a melting point of 55° C. or higher; (B) a polyhydric alcohol; and (C) an acrylic acid-based water-soluble polymer.

The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby improving properties of the finished drug.

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.

The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby improving properties of the finished drug.

Described herein are methods of treating or reducing the severity of thyroid eye disease (TED), as well as antibodies that bind and inhibit signaling through the insulin-like growth factor receptor 1, useful in the methods.

The present invention addresses the problem of providing a novel compound that has a thyroid-stimulating hormone receptor antagonistic activity and is useful for the treatment of thyroid-related diseases. The present invention relates to a nitrogen-containing condensed ring compound represented by formula (A-I) or a pharmacologically acceptable salt thereof. The present invention relates to a nitrogen-containing condensed ring compound represented by formula (A-I) or a pharmacologically acceptable salt thereof. The compound or the pharmacologically acceptable salt thereof according to the present invention has an antagonistic activity against thyroid-stimulating hormone receptors and is therefore useful as a therapeutic agent for thyroid-related diseases (e.g., hyperthyroidism, Graves' disease, thyroid eye disease, and thyroid cancer) and others.